Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fosamac Reduces Multiple New Fracture Risk by up to 70% in Osteoporosis: Banyu Seminar
September 10, 2001
- Korosho Demands Budget of \18,745.5 Bil. for FY2002, Up 3.63%
September 10, 2001
- Combination of Thrombolytic, Cerebral Protective Agents Recommended for CI: MTP Seminar
September 10, 2001
- Korosho to Propose Healthcare System Reform at End of Sept.
September 10, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 10, 2001
- Goal Is 5 Years from Development to Approval: PMSB
September 10, 2001
- Latest Information Cannot Be Diffused Through Package Inserts: Seminar
September 10, 2001
- Bill for Revision of PAL to Be Submitted Next Diet Session
September 10, 2001
- BUSINESS NEWS IN BRIEF -2-
September 10, 2001
- To Bolster Globalization Based on Past Experiences: Mr Yoshino of Shionogi
September 10, 2001
- BUSINESS NEWS IN BRIEF -1-
September 10, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 10, 2001
- Additional Data Required for Sanwa Kagaku's SNK-860
September 10, 2001
- Kawasumi Potassium Adsorption Filter Recommended for Approval
September 10, 2001
- Toho Ties Up with Yakushin
September 10, 2001
- Banyu, Kyorin, Teijin to Start Immediate PMS for Montelukast, Alendronate
September 10, 2001
- Cerivastatin's Setback to Favor Sankyo's Mevalotin
September 10, 2001
- World News in Brief
September 3, 2001
- IPLS to Focus on Changing Licensing Business -2-
September 3, 2001
- IPLS to Focus on Changing Licensing Business -1-
September 3, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…